Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause Article

sustainable development goals

authors

publication date

  • January 1, 2013

webpage

published in

keywords

  • Adverse outcomes
  • Cardiovascular
  • Cerebrovascular
  • Desvenlafaxine
  • Hepatic

start page

  • 47

end page

  • 56

volume

  • 20

issue

  • 1